Sign in
Stories
Biotech Funding and Nicotine Debate
Share
Advancements in Cancer Treatment and Mar...
Amgen's Obesity Prospects in Focus
Biopharma Innovations and FDA Decisions
ACTICOR BIOTECH: Financial Report Postpo...
ANJESO Drug Insight and Market Forecast
Acquisition Progress Amid Safety Concern
Overview
API
EXO Biologics, a Belgian biotech company, secures €16M funding to advance exosome therapies globally. Meanwhile, Zyn, a nicotine pouch by Phillip Morris, faces scrutiny over potential health risks and underage appeal.
Ask a question
How might EXO Biologics' funding impact the development of exosome therapies and the biotech industry?
In what ways could the scrutiny of Zyn and similar products influence the future regulation of alternative nicotine products?
What measures can regulators take to address concerns about Zyn's appeal to underage users and potential health risks?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Apr 2024
Coverage